Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.30 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25006022 | 0.76 | HTR2A (0.30) | — | |
| SCHEMBL23992759 | 0.72 | SLC6A4 (0.30) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL27281802 | 0.71 | JAK2 (0.33) | JAK2JAK1 | |
| SCHEMBL12523302 | 0.71 | JAK2 (0.38) | JAK2JAK1 | |
| SCHEMBL12523343 | 0.71 | JAK2 (0.38) | JAK2JAK1 | |
| SCHEMBL12523328 | 0.71 | JAK2 (0.38) | JAK2JAK1 | |
| SCHEMBL10296345 | 0.71 | JAK2 (0.33) | JAK2JAK1 | |
| SCHEMBL23958523 | 0.69 | JAK2 (0.32) | JAK2JAK1 | |
| SCHEMBL5226088 | 0.69 | HTR2A (0.31) | — | |
| SCHEMBL23690730 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211911-B2 | Compounds as kinase inhibitors | CHEN GUOQING PAUL (US) | 2012-07-03 | — | — | US | disclosed |
| US-20100048599-A1 | Compounds As Kinase Inhibitors | CHEN GUOQING PAUL | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048599-A1 | Compounds As Kinase Inhibitors | MAP3K1, MAP3K5, MAP3K6 | JAK2 30/4885JAK1 28/4885ATM 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.